open access

Vol 90, No 2 (2019)
ORIGINAL PAPERS Gynecology
Published online: 2019-02-28
Get Citation

Sensitivity and specificity of hr hPV E6/E7 mrna test in detecting cervical squamous intraepithelial lesion and cervical cancer

Dominik Pruski, Sonja Millert-Kalinska, Anna Lewek, Witold Kedzia
DOI: 10.5603/GP.2019.0011
·
Pubmed: 30860271
·
Ginekol Pol 2019;90(2):66-71.

open access

Vol 90, No 2 (2019)
ORIGINAL PAPERS Gynecology
Published online: 2019-02-28

Abstract

Objectives: The paper assess the relevance of HR HPV E6/E7 mRNA test in women with abnormal Pap results.  Material and methods: Between 2013–2014, 125 women were subjects to the enhanced diagnostics due to abnormal Pap results. According to The Bethesda system, if ASC-US, AGC, LSIL, ASC-H, HSIL or cancer cells were present, the result was abnormal. The patients underwent the enhanced diagnostics which included the following procedures: Pap smear collection for molecular assessment of HR HPV E6/E7 mRNA test, the colposcopic examination and biopsy of clinically suspicious areas.  Results: High-grade squamous intraepithelial lesions constituted the most frequent cervical pathology in women with abnormal Pap test results, as well as with the positive results of HR HPV E6/E7 mRNA test. Test sensitivity in patients with the histopathological diagnosis of high-grade squamous intraepithelial lesion was estimated at 86.1%.  Conclusions: HR HPV E6/E7 mRNA test identifying neoplastic lesions and cervical cancer is characterised by a high relevance which is reflected by means of sensitivity and specificity. In fact, test sensitivity and specificity increased with the age in the group of patients up to 50 years old. 

Abstract

Objectives: The paper assess the relevance of HR HPV E6/E7 mRNA test in women with abnormal Pap results.  Material and methods: Between 2013–2014, 125 women were subjects to the enhanced diagnostics due to abnormal Pap results. According to The Bethesda system, if ASC-US, AGC, LSIL, ASC-H, HSIL or cancer cells were present, the result was abnormal. The patients underwent the enhanced diagnostics which included the following procedures: Pap smear collection for molecular assessment of HR HPV E6/E7 mRNA test, the colposcopic examination and biopsy of clinically suspicious areas.  Results: High-grade squamous intraepithelial lesions constituted the most frequent cervical pathology in women with abnormal Pap test results, as well as with the positive results of HR HPV E6/E7 mRNA test. Test sensitivity in patients with the histopathological diagnosis of high-grade squamous intraepithelial lesion was estimated at 86.1%.  Conclusions: HR HPV E6/E7 mRNA test identifying neoplastic lesions and cervical cancer is characterised by a high relevance which is reflected by means of sensitivity and specificity. In fact, test sensitivity and specificity increased with the age in the group of patients up to 50 years old. 

Get Citation

Keywords

HPV E6/E7 mRNA; SIL; squamous intraepithelial lesion; HSIL

About this article
Title

Sensitivity and specificity of hr hPV E6/E7 mrna test in detecting cervical squamous intraepithelial lesion and cervical cancer

Journal

Ginekologia Polska

Issue

Vol 90, No 2 (2019)

Pages

66-71

Published online

2019-02-28

DOI

10.5603/GP.2019.0011

Pubmed

30860271

Bibliographic record

Ginekol Pol 2019;90(2):66-71.

Keywords

HPV E6/E7 mRNA
SIL
squamous intraepithelial lesion
HSIL

Authors

Dominik Pruski
Sonja Millert-Kalinska
Anna Lewek
Witold Kedzia

References (25)
  1. WHO/ICO Information centre on HPV and cervical cancer (HPV Information Centre). Human papillomavirus and related cancers in Europe. Summary report 2010. Barcelona, Spain: WHO/ ICO HPV Information Centre. : 2010.
  2. Elfström KM, Arnheim-Dahlström L, von Karsa L, et al. Cervical cancer screening in Europe: Quality assurance and organisation of programmes. Eur J Cancer. 2015; 51(8): 950–968.
  3. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6): 1374–1403.
  4. Wojciechowska Urszula, Didkowska Joanna. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Centrum Onkologii - Instytut im. Marii Skłodowskiej - Curie. . http://onkologia.org.pl/raporty/ (27/11/2017).
  5. Spaczyński M, Nowak-Markwitz E, Karowicz-Bilińska A, et al. Diagnostyka nowotworów narządów płciowych, Praktyczna ginekologia onkologiczna. Wielkopolskie Towarzystwo Onkologii Ginekologicznej, Poznań. 2012: 23–29.
  6. Kędzia W, Karowicz-Bilińska A, Spaczyński M. Nowotwory szyjki macicy, Praktyczna ginekologia onkologiczna. Wielkopolskie Towarzystwo Onkologii Ginekologicznej, Poznań, 2012. 2012: 91–110.
  7. Saslow D, Solomon D, Lawson H, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA: A Cancer Journal for Clinicians. 2012; 62(3): 147–172.
  8. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. CA: A Cancer Journal for Clinicians. 2002; 52(6): 342–362.
  9. Goldie S, Kim J, Wright T. Cost-Effectiveness of Human Papillomavirus DNA Testing for Cervical Cancer Screening in Women Aged 30 Years or More. Obstetrics & Gynecology. 2004; 103(4): 619–631.
  10. Karsa Lv, Arbyn M, Vuyst HDe, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Research. 2015; 1: 22–31.
  11. Mayrand MH, et al. et al.. HPV testing vs Papanicolaou screening tests for cervical cancer. NE J Med. 2007; 357: 1579–1588.
  12. Gatenby RA, Vincent TL. An evolutionary model of carcinogenesis. Cancer Res. 2003; 63(19): 6212–6220.
  13. Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005; 32 Suppl 1: S7–15.
  14. Miller CS. Pleiotropic mechanisms of virus survival and persistence. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100(2 Suppl): S27–S36.
  15. Cox JT. Management of women with cervical cancer precursor lesions. Obstet Gynecol Clin North Am. 2002; 29(4): 787–816.
  16. Sørbye SW, Fismen S, Gutteberg TJ, et al. HPV mRNA is more specific than HPV DNA in triage of women with minor cervical lesions. PLoS One. 2014; 9(11): e112934.
  17. Yao YL, Tian QF, Cheng B, et al. Human papillomavirus (HPV) E6/E7 mRNA detection in cervical exfoliated cells: a potential triage for HPV-positive women. J Zhejiang Univ Sci B. 2017; 18(3): 256–262.
  18. Perez Castro S, Iñarrea Fernández A, Lamas González MJ, et al. Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA. J Med Virol. 2013; 85(6): 1063–1068.
  19. Fontecha N, Basaras M, Hernáez S, et al. Assessment of human papillomavirus E6/E7 oncogene expression as cervical disease biomarker. BMC Cancer. 2016; 16(1): 852.
  20. Rokita W, Kedzia W, Pruski D, et al. Comparison of the effectiveness of cytodiagnostics, molecular identification of HPV HR and CINtecPLUS test to identify LG SIL and HG SIL. Ginekol Pol. 2012; 83(12): 894–898.
  21. Pruski D, Malkowska-Walczak B, Paluszkiewicz A, et al. The incidence of cervical intraepithelial neoplasia in a population of pregnant women with an abnormal cytology. Ginekol Pol. 2017; 88(1): 20–23.
  22. Ge Y, Christensen P, Luna E, et al. Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer. Cancer Cytopathol. 2017; 125(8): 652–657.
  23. Duvlis S, Popovska-Jankovic K, Arsova ZS, et al. HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women. J Med Virol. 2015; 87(9): 1578–1586.
  24. Granados R, Tellez-Safina H, Solis I, et al. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women. Diagn Cytopathol. 2017; 45(12): 1065–1072.
  25. Casagrande DC, Ribalta JCL, Leite KD, et al. Expression of human papillomavirus E6 and E7 oncoprotein mRNA in women with low-grade squamous intraepithelial lesions or less. Genet Mol Res. 2016; 15(1).

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl